Suven Pharmaceuticals Limited Total Assets
Suven Pharmaceuticals Limited total assets. Based on the latest financial reports, Suven Pharmaceuticals Limited (SUVENPHAR) holds total assets worth Rs30.32 Billion INR (≈ $327.87 Million USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Suven Pharmaceuticals Limited market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Suven Pharmaceuticals Limited (2019–2025)
Total assets of Suven Pharmaceuticals Limited from 2019 to 2025. This chart illustrates how Suven Pharmaceuticals Limited's total assets have evolved over time, based on quarterly financial data. See SUVENPHAR share price today for real-time trading data and today's change.
Suven Pharmaceuticals Limited - Asset Composition Analysis
Suven Pharmaceuticals Limited Total Assets Breakdown (March 2025)
Suven Pharmaceuticals Limited total assets breakdown as of March 2025. Suven Pharmaceuticals Limited's total assets of Rs30.32 Billion consist of 29.3% current assets and 70.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 2.8% |
| Accounts Receivable | Rs2.85 Billion | 9.4% |
| Inventory | Rs1.67 Billion | 5.5% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs638.90 Million | 2.1% |
| Goodwill | Rs6.55 Billion | 21.6% |
Asset Composition Trend (2019–2025)
This chart illustrates how Suven Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Suven Pharmaceuticals Limited (SUVENPHAR) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Suven Pharmaceuticals Limited's current assets represent 29.3% of total assets in 2025, a decrease from 49.8% in 2019.
- Cash Position: Cash and equivalents constituted 2.8% of total assets in 2025, up from 1.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 21.6% of total assets.
Suven Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Suven Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Suven Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.43 | 11.82 | 1.95 |
| Quick Ratio | 1.98 | 9.65 | 1.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs5.23 Billion | Rs11.56 Billion | Rs1.91 Billion |
Suven Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Suven Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.25 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 34.5% |
| Total Assets | Rs30.32 Billion |
| Market Capitalization | $4.40 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Suven Pharmaceuticals Limited's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Suven Pharmaceuticals Limited's assets grew by 34.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Suven Pharmaceuticals Limited (2019–2025)
The table below shows the annual total assets of Suven Pharmaceuticals Limited from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs30.32 Billion ≈ $327.87 Million |
+34.50% |
| 2024-03-31 | Rs22.54 Billion ≈ $243.77 Million |
+14.67% |
| 2023-03-31 | Rs19.66 Billion ≈ $212.59 Million |
+7.44% |
| 2022-03-31 | Rs18.30 Billion ≈ $197.86 Million |
+24.08% |
| 2021-03-31 | Rs14.74 Billion ≈ $159.46 Million |
+25.72% |
| 2020-03-31 | Rs11.73 Billion ≈ $126.84 Million |
+49.78% |
| 2019-03-31 | Rs7.83 Billion ≈ $84.68 Million |
-- |
About Suven Pharmaceuticals Limited
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research servic… Read more